Liquidity and Management's Plans (Details) (USD $)	1 Months Ended			3 Months Ended	9 Months Ended		12 Months Ended		9 Months Ended
	May 31, 2012	Jan. 31, 2012	Mar. 31, 2011	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2012 Maximum [Member]	Sep. 30, 2012 Minimum [Member]	Feb. 28, 2012 Expired [Member]	Feb. 24, 2012 Active [Member]	Sep. 30, 2012 Contract Revenue [Member]
Liquidity and Management's Plan (Textual) [Abstract]
Securities for potential future issuance											$ 50,000,000	$ 40,000,000
Estimated cost in connection to reformulation project									800,000	600,000
Deferred contract					16,505,920		14,154,720						2,500,000
Liquidity and Management's Plan (Additional Textual) [Abstract]
Contract revenue from the Endo license agreement					45,000,000
Previously deferred contract revenue					100,000
Net proceeds from a private placement offering of Common Stock in March 2011			14,000,000
Net royalties under the meda agreements				2,659,728		2,693,954	1,000,000
Exercise of Common Stock warrants					135,000	1,749,259	1,700,000
Contract revenue from licensing and supply agreement							300,000
Research revenues from various contractor agreements					13,375	226,843	200,000
Exercise of Common Stock options					1,873,397	349,676	300,000
Expiration of potential future issuance					2015-02
Cash and cash equivalents				15,119,420	31,319,153	15,119,420	10,750,205	18,208,659
Cash from operations					19,650,639	(18,924,204)
Stockholders' equity					11,029,947		4,120,393
Upfront non-refundable milestone payment from Endo	15,000,000	30,000,000
Aggregate Anticipated cash For Clinical research	$ 45,000,000